Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker FATE · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis NCT07570862 · Lupus Nephritis, Systemic Lupus Erythematosus FT819 | FATE Fate Therapeutics | Phase 2 | Recruiting | 53 | Jul 1, 2029 | Registry ↗ |
| Sep 2, 2026 | FT839 in Autoimmune Diseases NCT07800871 · ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory M… FT839 | FATE Fate Therapeutics | Phase 1/2 | Recruiting | 446 | Oct 2028 | Registry ↗ |
| Sep 2, 2026 | FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Soli… NCT07216105 · Non-Small Cell Lung Cancer, Colorectal Cancer FT836, Cetuximab | FATE Fate Therapeutics | Phase 1 | Recruiting | 119 | Jan 2028 | Registry ↗ |
| May 22, 2026 | A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease NCT06308978 · Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Va… FT819, Fludarabine | FATE Fate Therapeutics | Phase 1 | Recruiting | 244 | Sep 30, 2027 | Registry ↗ |
| Mar 19, 2026 | FT819 in Subjects With B-cell Malignancies NCT04629729 · Lymphoma, B-Cell, Chronic Lymphocytic Leukemia FT819, Cyclophosphamide | FATE Fate Therapeutics | Phase 1 | Active, not recruiting | 54 | Jun 18, 2025 | Registry ↗ |
| Dec 12, 2025 | FT576 in Subjects With Multiple Myeloma NCT05182073 · Multiple Myeloma, Myeloma FT576 (Allogenic CAR NK cells with BCMA expression), Cyclop… | FATE Fate Therapeutics | Phase 1 | Completed | 31 | Sep 20, 2024 | Registry ↗ |
| Dec 9, 2025 | FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Sol… NCT06241456 · Advanced Solid Tumor FT825, Fludarabine | FATE Fate Therapeutics | Phase 1 | Recruiting | 351 | May 1, 2029 | Registry ↗ |
| Aug 22, 2025 | FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) NCT05950334 · Relapsed/Refractory B-Cell Lymphoma FT522, Rituximab | FATE Fate Therapeutics | Phase 1 | Completed | 20 | Jun 6, 2025 | Registry ↗ |
| Oct 26, 2023 | FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies NCT04245722 · Lymphoma, B-Cell, Chronic Lymphocytic Leukemia FT596, Cyclophosphamide | FATE Fate Therapeutics | Phase 1 | Terminated | 98 | Sep 27, 2023 | Registry ↗ |
| Oct 26, 2023 | FT516 in Subjects With Advanced Hematologic Malignancies NCT04023071 · Acute Myelogenous Leukemia, B-cell Lymphoma FT516, Rituximab | FATE Fate Therapeutics | Phase 1 | Terminated | 72 | Oct 23, 2023 | Registry ↗ |
| Sep 21, 2023 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors NCT05395052 · Non Small Cell Lung Cancer, Colorectal Cancer FT536, Cyclophosphamide | FATE Fate Therapeutics | Phase 1 | Terminated | 5 | Aug 11, 2023 | Registry ↗ |
| Sep 21, 2023 | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors NCT05069935 · Solid Tumor, Adult FT538, Cyclophosphamide | FATE Fate Therapeutics | Phase 1 | Terminated | 16 | Aug 11, 2023 | Registry ↗ |
| Sep 21, 2023 | FT538 in Subjects With Advanced Hematologic Malignancies NCT04614636 · Acute Myeloid Leukemia, AML, Adult FT538, Cyclophosphamide | FATE Fate Therapeutics | Phase 1 | Terminated | 42 | Jul 13, 2023 | Registry ↗ |
| Sep 21, 2023 | FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors NCT04551885 · Solid Tumor, Adult FT516, Avelumab | FATE Fate Therapeutics | Phase 1 | Terminated | 12 | Aug 11, 2023 | Registry ↗ |
| Sep 21, 2023 | Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500… NCT04106167 · Advanced Solid Tumor, Lymphoma Allogeneic natural killer (NK) cell | FATE Fate Therapeutics | — | Terminated | 20 | Aug 11, 2023 | Registry ↗ |
| Jul 6, 2023 | FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma NCT05934097 · Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hod… FT596, Cyclophosphamide | FATE Fate Therapeutics | Phase 1 | Withdrawn | 0 | May 2026 | Registry ↗ |
| May 1, 2023 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced… NCT03841110 · Advanced Solid Tumors, Lymphoma FT500, Nivolumab | FATE Fate Therapeutics | Phase 1 | Completed | 37 | Nov 15, 2022 | Registry ↗ |
| Feb 8, 2023 | Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies NCT02743351 · Hematologic Malignancies, Acute Myeloid Leukemia ProTmune, Control Arm | FATE Fate Therapeutics | Phase 1/2 | Completed | 96 | Dec 4, 2020 | Registry ↗ |
| Aug 29, 2022 | Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunothe… NCT04093622 · Hematological Malignancy Genetically engineered NK cells | FATE Fate Therapeutics | — | Terminated | 2 | Apr 9, 2020 | Registry ↗ |
| Nov 30, 2021 | The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB… NCT01627314 · Hematologic Malignancies ProHema-CB, Untreated CB | FATE Fate Therapeutics | Phase 2 | Terminated | 62 | Mar 2016 | Registry ↗ |
| Nov 22, 2021 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Sol… NCT03319459 · HER2 Positive Gastric Cancer, Colorectal Cancer FATE-NK100, Cetuximab | FATE Fate Therapeutics | Phase 1 | Completed | 44 | May 29, 2020 | Registry ↗ |
| Oct 10, 2018 | A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Di… NCT02354443 · Metabolic Disorders ProHema-CB Transplant | FATE Fate Therapeutics | Phase 1 | Terminated | 1 | Dec 2016 | Registry ↗ |
| Oct 10, 2018 | A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies NCT02354417 · Hematologic Malignancies Biological: ProHema-CB | FATE Fate Therapeutics | Phase 1 | Terminated | 3 | Dec 2016 | Registry ↗ |
| Sep 12, 2016 | Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit NCT01527838 · Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease Single FT1050 treated UCB unit | FATE Fate Therapeutics | Phase 1 | Completed | 10 | Oct 2013 | Registry ↗ |
24 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:15 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances